Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds By: Newsfile July 05, 2024 at 08:00 AM EDT Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.For additional information, visit the Company's website, www.phiopharma.com. Contact:Phio Pharmaceuticals Corp.ir@phiopharma.com PR Contact Michael Adams Bridge View Mediaadams@bridgeviewmedia.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215358 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds By: Newsfile July 05, 2024 at 08:00 AM EDT Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.For additional information, visit the Company's website, www.phiopharma.com. Contact:Phio Pharmaceuticals Corp.ir@phiopharma.com PR Contact Michael Adams Bridge View Mediaadams@bridgeviewmedia.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215358
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.About Phio Pharmaceuticals Corp.Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.For additional information, visit the Company's website, www.phiopharma.com. Contact:Phio Pharmaceuticals Corp.ir@phiopharma.com PR Contact Michael Adams Bridge View Mediaadams@bridgeviewmedia.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215358